Breaking Finance News

A statement released earlier today by Northland Securities about Obalon Therapeutics Inc (NASDAQ:OBLN) bumps the target price to $6.00

Boasting a price of $10.72, Obalon Therapeutics Inc (NASDAQ:OBLN) traded 2.67% higher on the day. With the last stock price close up 5.23% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Obalon Therapeutics Inc has recorded a 50-day average of $9.71 and a two hundred day average of $9.50. Volume of trade was up over the average, with 128,606 shares of OBLN changing hands over the typical 53,480

Northland Securities bumped up the target of Obalon Therapeutics Inc (NASDAQ:OBLN) to $6.00 stating a potential downside of -0.44%.

Performance Chart

Obalon Therapeutics Inc (NASDAQ:OBLN)

With a total market value of $0, Obalon Therapeutics Inc has with a one year low of $8.27 and a one year high of $15.88 .

More About Obalon Therapeutics Inc (NASDAQ:OBLN)

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *